Health ❯ Pharmaceuticals ❯ Cancer Treatment

Prostate Cancer

Therapeutic Candidates Drug Development Therapeutics

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Investors have until January 9, 2026 to move for lead‑plaintiff status in the Southern District of Indiana case.

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures